Stomach Cancer
Stomach cancer, also known as gastric cancer, primarily develops from the lining of the stomach, with most cases being gastric adenocarcinomas that originate in gland cells. Early symptoms may include heartburn, nausea, and loss of appetite, while later stages may involve weight loss, jaundice, and difficulty swallowing, with potential spread to other body parts such as the liver and lungs.
Health Outcomes
- Accelerated Recovery of Chemotherapy-Induced Myelosuppression
- Improved Gastric Survival
- Improved H Pylori Eradication Rates
- Improved Intestinal Metaplasia Regression
- Improved Pathological Response
- Improved Protection Against Helicobacter pylori
- Improved Survival Through Gastric Conditions
- Improved Survival in Digestive Environment
- Improved Survival in Gastroduodenal Environment
- Increased Antiangiogenic Activity
- Increased Gastric Epithelial Stem/Progenitor Cell Proliferation
- Increased H. pylori Eradication Rate
- Increased Mitogenic Activity
- Increased Reduced Glutathione Level
- Increased Serum Pepsinogen Activity
- No Influence on Oropharyngeal Microbiota
- No Significant Change in Gastrointestinal Symptoms
- Reduced CEA Levels
- Reduced Cancer-Specific Mortality
- Reduced Cell Adhesion
- Reduced Chemotherapy-Induced Nausea and Vomiting
- Reduced Expression of Cag Pathogenicity Island Genes in H. pylori
- Reduced Gastric Cell Death
- Reduced Gastric Epithelial Proliferation Signaling
- Reduced Gastric Ornithine Decarboxylase Activity
- Reduced Gastric Volume
- Reduced Gastrointestinal Toxicity
- Reduced H. pylori Infection Severity
- Reduced Helicobacter Pylori Infection
- Reduced IL-8 Production in Gastric Epithelial Cells
- Reduced Inflammatory Response to Helicobacter pylori
- Reduced Pepsinogen I Level
- Reduced Pepsinogen Production
- Reduced Time to Enteral Nutrition Transition
- Suppressed H. Pylori Infection
- Suppressed H. pylori Growth In Vivo